• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

Vogel A, Cervantes A, Chau I, Daniele B, Llovet J M, Meyer T, Nault J-C, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech C J, Arnold D, Martinelli E

机构信息

Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.

Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.

出版信息

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.

DOI:10.1093/annonc/mdy308
PMID:30285213
Abstract
摘要

相似文献

1
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.肝细胞癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.
2
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌：欧洲肿瘤内科学会临床实践诊断、治疗及随访指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.
3
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.华氏巨球蛋白血症：欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146.
4
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.原发性皮肤淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133.
5
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.霍奇金淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080.
6
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.从肝癌的诊断到治疗：发达国家和发展中国家共同面临的流行问题。
World J Gastroenterol. 2017 Aug 7;23(29):5282-5294. doi: 10.3748/wjg.v23.i29.5282.
7
Hepatocellular Carcinoma: Updates to Screening and Diagnosis.肝细胞癌：筛查和诊断的更新。
J Natl Compr Canc Netw. 2018 May;16(5S):663-665. doi: 10.6004/jnccn.2018.0052.
8
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.非上皮性卵巢癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv1-iv18. doi: 10.1093/annonc/mdy001.
9
How we approach it: treatment options for hepatocellular carcinoma.我们如何应对：肝细胞癌的治疗选择
Am J Gastroenterol. 2018 Jun;113(6):791-794. doi: 10.1038/s41395-018-0008-9. Epub 2018 May 1.
10
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.骨肉瘤：ESMO-儿童癌症-欧洲骨肉瘤协作组诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310.

引用本文的文献

1
Voacangine targeting of PI3K/Akt/ERK via the knockdown of inflammation in DEN-induced liver cancer: in vivo and in silico approach.通过抑制二乙基亚硝胺诱导的肝癌炎症来靶向PI3K/Akt/ERK的沃卡星：体内和计算机模拟方法
J Mol Histol. 2025 Aug 29;56(5):281. doi: 10.1007/s10735-025-10577-2.
2
Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication.肿瘤大小对肝动脉造影和C型臂CT引导下消融术（HepACAGA）结果的影响：>3 cm并非绝对禁忌证。
Cardiovasc Intervent Radiol. 2025 Aug 26. doi: 10.1007/s00270-025-04167-8.
3
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.
瑞戈非尼用于真实世界实践中的肝细胞癌（REFINE）：一项前瞻性观察性研究。
Liver Cancer. 2024 Dec 18;14(4):391-407. doi: 10.1159/000542285. eCollection 2025 Aug.
4
TACE Sequential to Radiofrequency Ablation versus RFA Alone in Hepatocellular Carcinoma Within Milan Criteria.米兰标准内肝细胞癌中经动脉化疗栓塞术序贯射频消融与单纯射频消融的比较
J Hepatocell Carcinoma. 2025 Aug 12;12:1795-1805. doi: 10.2147/JHC.S534039. eCollection 2025.
5
Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.肝细胞癌患者获得全身治疗的差异：来自国际肝癌协会的分析
Lancet Reg Health Eur. 2025 Jul 31;57:101408. doi: 10.1016/j.lanepe.2025.101408. eCollection 2025 Oct.
6
Impact of Multidisciplinary Continuity of Care on Postoperative Outcomes in Liver Cancer Surgical Patients.多学科连续性护理对肝癌手术患者术后结局的影响
J Multidiscip Healthc. 2025 Aug 6;18:4749-4759. doi: 10.2147/JMDH.S527399. eCollection 2025.
7
Detection of early-stage hepatocellular carcinoma: a retrospective evaluation of ultrasonography surveillance and surveillance adherence.早期肝细胞癌的检测：超声监测及监测依从性的回顾性评估
Transl Gastroenterol Hepatol. 2025 Jun 11;10:46. doi: 10.21037/tgh-24-119. eCollection 2025.
8
Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma.门静脉高压对肝细胞癌肝切除术后结局的阶段特异性影响。
Hepatol Int. 2025 Jul 30. doi: 10.1007/s12072-025-10879-3.
9
HCC case management-related challenges: Think outside the box!与肝癌病例管理相关的挑战：跳出框框思考！
ILIVER. 2023 Aug 27;2(3):143-145. doi: 10.1016/j.iliver.2023.08.001. eCollection 2023 Sep.
10
CCL16 inhibits tumor proliferation and metastasis in HCC by impacting CK19 phenotype.CCL16 通过影响CK19表型抑制肝癌的肿瘤增殖和转移。
ILIVER. 2024 May 20;3(2):100096. doi: 10.1016/j.iliver.2024.100096. eCollection 2024 Jun.